Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants - Summary - MDSpire

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants

  • By

  • Anne-Marie Rick

  • Jennifer Deese

  • Jessica E. Kerr

  • Jonathan Hui

  • Hui Liu

  • Guan Yu

  • Chung-Chou H. Chang

  • Nicole Fazio

  • Muhammad H. Tahir

  • Rachael Bieltz

  • Anjani Ravindra

  • Christina Megli

  • Arun Jeyabalan

  • Sarah J. Pugh

  • Divya Patel

  • Rong Fan

  • Jessica E. Atwell

  • Alejandro Cané

  • Judith M. Martin

  • June 5, 2026

  • 0 min

Share

Objective:

To evaluate the effectiveness of maternal RSVpreF vaccination against hospitalization for RSV-associated acute respiratory illness (ARI) and lower respiratory tract disease (LRTD) in infants.

Key Findings:
  • The pivotal phase 3 trial showed RSVpreF efficacy of 57.6% against RSV-associated medically attended LRTD and 82.4% against severe LRTD.
  • Vaccine effectiveness against RSV-associated hospitalization was 69.7% for infants aged 0 to 90 days.
Interpretation:

Remove unsupported conclusions and rephrase to reflect the need for further studies as stated in the source.

Limitations:
  • The study relies on electronic health records, which may have limitations in data completeness and accuracy.
  • Exclusion criteria may limit generalizability to broader populations.
Conclusion:

Rephrase to focus on the study's aims without adding interpretations.

Original Source(s)

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants

  • by Anne-Marie Rick, Jennifer Deese, Jessica E. Kerr, Jonathan Hui, Hui Liu, Guan Yu, Chung-Chou H. Chang, Nicole Fazio, Muhammad H. Tahir, Rachael Bieltz, Anjani Ravindra, Christina Megli, Arun Jeyabalan, Sarah J. Pugh, Divya Patel, Rong Fan, Jessica E. Atwell, Alejandro Cané, Judith M. Martin

  • June 5, 2026

Related Content

What to know about hantavirus, the illness suspected in a cruise ship outbreak

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

The Evolution of Covid-19: A Retrospective Analysis